Gilteritinib (Xospata®) for Relapsed/Refractory Acute Myeloid Leukemia

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an  FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients fully benefit from this medication.